ANRO

NYSE Healthcare

Alto Neuroscience, Inc. Common Stock

Biotechnology

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

๐Ÿ“Š Market Data
Price$24.94
Volume207,730
Market Cap874.22M
Beta2.060
RSI (14-Day)46.5
200-Day MA$13.31
50-Day MA$22.50
52-Week High$28.44
52-Week Low$2.12
Forward P/E-10.96
Price / Book5.27
๐ŸŽฏ Investment Strategy Scores

ANRO scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 95/100โ–ฒ +3
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 12/100โ–ฒ +7
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 27/100โ–ผ -29
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (95/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (5/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find ANRO in your text

Paste any article, transcript, or post โ€” the tool will extract ANRO and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.